These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34864823)

  • 1. Differentiation therapy for myeloid malignancies: beyond cytotoxicity.
    Stubbins RJ; Karsan A
    Blood Cancer J; 2021 Dec; 11(12):193. PubMed ID: 34864823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
    Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
    Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
    Kojima K
    Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview: A New Era of Cancer Genome in Myeloid Malignancies.
    Kiyoi H
    Oncology; 2015; 89 Suppl 1():1-3. PubMed ID: 26551625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
    Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
    Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of the inflammasome in myeloid malignancies.
    Chakraborty S; Shapiro LC; de Oliveira S; Rivera-Pena B; Verma A; Shastri A
    Blood Cancer J; 2021 Sep; 11(9):152. PubMed ID: 34521810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.
    Silva G; Cardoso BA; Belo H; Almeida AM
    PLoS One; 2013; 8(1):e53766. PubMed ID: 23320102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
    J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic therapies in MDS and AML.
    Griffiths EA; Gore SD
    Adv Exp Med Biol; 2013; 754():253-83. PubMed ID: 22956506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.